Shopping Cart
Remove All
Your shopping cart is currently empty
Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $173 | In Stock | In Stock | |
| 5 mg | $289 | In Stock | In Stock | |
| 10 mg | $455 | In Stock | In Stock | |
| 25 mg | $818 | In Stock | In Stock | |
| 50 mg | $1,190 | In Stock | In Stock | |
| 100 mg | $1,630 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $279 | In Stock | In Stock |
| Description | Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing. |
| Targets&IC50 | D489A (RSV,Mutant strain):> 10μM (EC50), RSV (WT):0.003 μM (EC50), RSV F:3 nM (EC50), D486N (RSV,Mutant strain):2.1 μM (EC50) |
| In vitro | With EC50/EC90 values (μM) of 0.003/0.005 (WT), 2.1/10.0 (D486N), and >10/>10 (D489A), Ziresovir exhibits different efficacy in Wild Type (WT) and Mutant Strains RSV, respectively[1].Inhibiting the RSV F protein-induced cell–cell fusion process, RO-0529 (100 nM; 4 d) suppresses the syncytia formation induced by the RSV F protein[1]. |
| In vivo | Ziresovir (12.5 mg/kg, 50 mg/kg; p.o.; twice daily; 4 d) reduces RSV titer in the mouse lung[1]. With a single oral dose of 10 mg/kg, Ziresovir exhibits good exposure and 32% bioavailability in male Wistar-Han rats[1]. A single oral dose of 150 mg/kg results in higher lung distribution than plasma in CD-1 mice[1]. |
| Synonyms | RO-0529, AK0529 |
| Molecular Weight | 439.53 |
| Formula | C22H25N5O3S |
| Cas No. | 1422500-60-4 |
| Smiles | Cc1ccc2nc(nc(NCC3(N)COC3)c2c1)N1CCS(=O)(=O)c2ccccc2C1 |
| Relative Density. | 1.390 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 38 mg/mL (86.46 mM), Sonication and heating are recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.55 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.